ELEKTA B SHS UNSP/ADR - EKTAY STOCK NEWS

Elekta announced the appointment of Tobias Hägglöv as the new Chief Financial Officer effective February 1, 2022, succeeding Johan Adebäck. Hägglöv brings extensive finance and IT expertise, previously serving as CFO at Recipharm and holding senior roles at Electrolux and SAS. CEO Gustaf Salford expressed confidence in Hägglöv's ability to add value amidst Elekta's ACCESS 2025 strategy. Adebäck will transition to a new role focusing on the company's Resilience and Excellence Program.

Elekta will present its second quarter 2021/22 results on November 25 at 10:00 a.m. CET, following the release of its interim report at 7:30 a.m. CET on the same day. The presentation will be conducted by President and CEO Gustaf Salford and CFO Johan Adebäck, including a Q&A session. Participants can join via a phone conference or watch the webcast. Elekta is a leader in precision radiation therapy, committed to innovative solutions in cancer care.

On August 25, 2021, shareholders of Elekta approved the establishment of the Elekta Foundation at the Annual General Meeting. This foundation aims to enhance access to cancer care in low- and middle-income countries, aligning with Elekta's ESG strategy. The foundation will focus on raising awareness for cancer prevention, strengthening healthcare infrastructure, and expanding education for healthcare professionals. Elekta's Chairman, Dr. Laurent Leksell, emphasized the need for improved cancer care access, particularly for women's health issues in Africa. The foundation will operate under the Swedish Foundations Act.

Elekta AB held its Annual General Meeting on August 25, 2021, via postal vote due to Covid-19. Key resolutions included the discharge of the Board from liability for the 2020/21 financial year and a dividend of SEK 2.20 per share, paid in two installments. The Board was confirmed with an increase in remuneration and Ernst & Young re-elected as auditor. The Performance Share Plan 2021 was established, linked to Elekta’s Total Shareholder Return relative to the OMXS30 Index. Additionally, the company committed SEK 35 million to establish a philanthropic foundation for enhancing cancer care.

Elekta (EKTA-B.ST) has established a permanent presence in Jakarta, Indonesia, to enhance cancer care access. With over 275 million residents and fewer than 80 active linear accelerators, Indonesia faces a critical gap in radiation therapy resources. Elekta aims to address this by improving service, support, and order fulfillment for customers, ultimately enhancing treatment options for patients. This initiative underscores Elekta's commitment to organic growth and meeting the demand for modern cancer care in underserved markets.

Elekta (EKTAY) announced a significant order from GenesisCare for 27 Flexitron® brachytherapy afterloader systems, enhancing cancer treatment capabilities across U.S. centers. This partnership aims to improve patient care by utilizing high-dose rate (HDR) brachytherapy, which is recognized for its precision and cost-effectiveness. The Flexitron system, used globally in about two-thirds of brachytherapy centers, facilitates efficient and safe treatment. Elekta's CEO highlighted their commitment to providing access to advanced cancer care through this collaboration.

Elekta has presented 36 abstracts showcasing the technical capabilities of the Elekta Unity MR-Linac at the AAPM Annual Meeting. Conducted across 14 leading cancer centers globally, the research highlights the system's benefits in personalized radiation therapy. Key findings include the effectiveness of MR-guided radiation therapy (MRgRT) for intramuscular tumors, real-time motion tracking for abdominal tumors, and potential clinical applications of quantitative relaxometry for prostate cancer treatment. Elekta continues to expand the MR-Linac Consortium to enhance data collection and access to advanced radiation medicine.